Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Transplantation. 2018 Oct;102(10):1762–1767. doi: 10.1097/TP.0000000000002202

Table 3.

Unadjusted and adjusted hospitalization costs based on VAD Utilization

Era 1 (2002 – 2006)
N=649 (22.4%)
Era 2 (2007 – 2011)
N=1028 (35.5%)
Era 3 (2012 – 2016)
N=1219 (42.1%)
p-value*

Overall Era 1 vs. Era 2 Era 2 vs. Era 3

Unadjusted costs
  No VAD $661,353 ($566,546– $772,024) $663,489 ($572,798– $768,540) $596,058 ($517,596– $686,415) 0.056 0.953 0.029
  With VAD $986,549 ($723,476– $1,345,283) $1,096,136 ($917,845– $1,309,061) $917,043 ($788,634– $1,066,360) 0.197 0.533 0.072
Adjusted costs
  No VAD $721,882 ($471,513– $1,105,194 $721,813 ($470,717– $1,106,853 $612,681 ($399,713– $939,119) 0.002 0.999 < 0.001
  With VAD $1,273,933 ($542,009– $2,994,241) $1,176,332 ($512,326– $2,700,933) $975,842 ($425,680– $2,237,049) 0.108 0.672 0.068
*

p-values from generalized linear mixed models

Cost expressed as least squares mean (Lower and Upper 95% confidence interval), inflated to 2016 dollars